View AstraZeneca's Q3 Earnings Report
FiercePharma says: AstraZeneca posted strong third-quarter numbers and boosted its full-year forecast by a whopping 40 cents per share. But one of the biggest pieces of news to come out of the company's Q3 report is a $520 million tentative agreement with the U.S. Attorney's Office in Philadelphia. Like several other drugmakers who've announced big settlements this year, AstraZeneca was facing a probe into alleged off-label marketing of a drug. In this case, the antipsychotic Seroquel. Read more of our coverage here...
- US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.
- US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER.
- Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.
AZ's Website: http://www.astrazeneca.com/